Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 730
- Registration Number
- NCT03703297
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
- Conditions
- Interventions
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Spanish Oncology Genito-Urinary Group
- Target Recruit Count
- 32
- Registration Number
- NCT03702179
- Locations
- 🇪🇸
Instituto Catalán de Oncología Badalona, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Centro Oncológico de Galicia, La Coruña, Spain
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT03693612
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1246
- Registration Number
- NCT03682068
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Ulrich Keilholz
- Target Recruit Count
- 18
- Registration Number
- NCT03624231
- Locations
- 🇩🇪
Charité Comprehensive Cancer Center, Berlin, Germany
🇩🇪Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany
🇩🇪Vivantes Klinikum Neukölln, Berlin, Germany
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionDrug: CarboplatinProcedure: Computed TomographyBiological: DurvalumabDrug: Gemcitabine HydrochlorideProcedure: Magnetic Resonance ImagingDrug: Nab-paclitaxelBiological: Personalized Synthetic Long Peptide VaccineDrug: Poly ICLCBiological: Sacituzumab GovitecanBiological: Tremelimumab
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT03606967
- Locations
- 🇺🇸
Moffitt Cancer Center at Wesley Chapel, Wesley Chapel, Florida, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT03598816
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03581487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Matthew Galsky
- Target Recruit Count
- 26
- Registration Number
- NCT03557918
- Locations
- 🇺🇸
University of Kansas Medical Center Research Institute, Inc., Westwood, Kansas, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Huntsman Cancer Institute University of Utah, Salt Lake City, Utah, United States
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2024-03-06
- Target Recruit Count
- 121
- Registration Number
- NCT03549715
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷Centre Eugène Marquis, Rennes, France
🇫🇷Groupe Hospitalier Pitié-Salpetrière, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.